EV Biologics Corp., a Wyoming-based biotechnology company, has engaged Foley to facilitate the propriety development of its exosome technology and technical innovation.
In its announcement, the company cited Foley’s standing at the top of intellectual property law in biotechnology and organics and its specialty in stem cell and extracellular vesicle technology.
Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer.
Related News
July 14, 2025
Press Releases
Foley Adds Litigation Partner Matt Caplan in San Francisco, Strengthening Technology and Health Care Sector Capabilities
Foley & Lardner LLP announced today that Matt Caplan has joined the firm’s San Francisco office as a partner in its Commercial Litigation Practice Group and Innovative Technology and Health Care & Life Sciences Sectors.
July 8, 2025
Press Releases
Foley Expands Tax Capabilities with Addition of Partner David Morris in Salt Lake City
Foley & Lardner LLP announced today that David Morris has joined the firm’s Salt Lake City office as a partner in its Taxation Practice Group.
June 5, 2025
Press Releases
Foley Secures Top Rankings in Chambers USA 2025
Foley & Lardner LLP is proud to once again be recognized by Chambers & Partners as one of the leading law firms in the country in the 2025 edition of Chambers USA: America’s Leading Lawyers for Business.